1.1Ankyrin repeats bind Gremlin2
Solvent-exposed residues on tandem ankyrin repeats form the binding surface. A receptor competition assay selects repeat proteins that occupy the Gremlin2 contact surface used by TGF-β receptor 1.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Solvent-exposed residues on tandem ankyrin repeats form the binding surface. A receptor competition assay selects repeat proteins that occupy the Gremlin2 contact surface used by TGF-β receptor 1.
A yeast display library varies heavy chain CDR2 while holding the other five CDRs fixed. Screening identifies sequence variants that bind Gremlin2, and a receptor competition assay measures whether the resulting antibodies block receptor binding.
A compact immunoglobulin framework positions three binding loops on one polypeptide. Selection for Gremlin2 binding followed by receptor competition screening identifies domains that block the Gremlin2–receptor interaction.
Three exposed loops on the fibronectin type III domain form an autonomous binding surface. Display selection enriches loop variants that bind Gremlin2, and receptor competition measurements identify variants that obstruct the receptor contact surface.
A display library pairs a fixed heavy chain with light chains that differ in CDR3 sequence. Gremlin2 binding and receptor competition assays identify alternative CDR3 sequences that retain the interaction-blocking function.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
The paired heavy and light chains form a capture antibody for measuring gremlin 2 in conditioned cell culture fluid. The antibody is immobilized through its Fc region on protein G agarose in a small flow-through column. Clarified culture fluid passes through the column, and a wash removes unbound material. The captured protein is eluted and quantified by liquid chromatography with mass spectrometry using gremlin 2 reference samples.
A human kappa constant domain replaces a lambda constant domain in a light-chain construct carrying the three specified light-chain binding loops. The kappa domain joins directly to the carboxyl terminus of the light-chain variable region, and the resulting light chain is coexpressed with the heavy chain carrying the three specified heavy-chain binding loops. Nonreducing electrophoresis checks chain assembly, and a receptor competition assay measures inhibition of gremlin 2 binding.
A 384-well plate carries immobilized extracellular domains of transforming growth factor beta receptor 1. Each well receives a 20 µL mixture of labeled gremlin 2 and antibody after a 30-minute preincubation, with eight antibody concentrations spaced threefold apart. After a 60-minute binding step, the plate is washed and the retained label is measured. Wells containing gremlin 2 alone provide the reference signal for fractional inhibition.
A two-channel microfluidic culture device holds lung epithelial cells and lung fibroblasts on opposite sides of a porous membrane. A pump introduces gremlin 2 and the paired-chain antibody into the fibroblast channel through a fluid mixer upstream of the culture chamber. Imaging measures deposited collagen in the fibroblast layer. Parallel channels receiving gremlin 2 alone provide a reference for the collagen response.
A surface plasmon resonance instrument uses a flow cell carrying the immobilized extracellular domain of transforming growth factor beta receptor 1 and a reference flow cell prepared without receptor. A fixed concentration of gremlin 2 is mixed with serial dilutions of the paired-chain antibody and injected over both cells at the same flow rate. The instrument subtracts the reference signal and compares the receptor-channel response with the response from gremlin 2 alone. The resulting concentration series gives a receptor competition curve.
Software inserts the three heavy-chain binding loops and three light-chain binding loops into candidate human variable-region frameworks and enumerates heavy and light framework pairings. A liquid handler combines the corresponding expression plasmids in individual wells of a mammalian cell culture plate. Plate measurements report secreted antibody concentration and inhibition of gremlin 2 binding to the receptor. Software ranks the pairs by inhibition at a matched antibody concentration.
The heavy chain variable region contains CDR1, CDR2, and CDR3 from SEQ ID NO. 1, 2, and 3, respectively. An IgG1 constant region supplies the CH1, hinge, CH2, and CH3 segments for assembly with the corresponding light chain.
The light chain variable region contains CDR1, CDR2, and CDR3 from SEQ ID NO. 4, 5, and 6, respectively. A kappa constant domain fused to the variable region pairs with the CH1 domain of the corresponding heavy chain.
An expression cassette encodes a cleavable secretion signal upstream of the light chain containing the three specified CDRs. The signal directs the nascent light chain into the endoplasmic reticulum and is cleaved during processing before secretion of the assembled antibody.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A recombinant antibody or a fragment thereof, comprising a variable light chain (VL) domain and a variable heavy chain (VH) domain, wherein the VL domain comprises a first light chain complementarity determining region (CDR-L1), a second light chain CDR (CDR-L2) and a third light chain CDR (CDR-L3), and the VH domain comprises a first heavy chain CDR (CDR-H1), a second heavy chain CDR (CDR-H2) and a third heavy chain CDR (CDR-H3), wherein the CDR-L1, CDR-L2, CDR-L3, CDR-H1, CA · US 2022/0348652 A1 · claim 1
TABLE 2 Amino acid sequences of the VL and VH domains of the recombinant scFv SEQ ID Domain Amino acid sequence NO VL MDAMKRGLCCVLLLCGAVFVSPSASNIVLTQSPKS 6 MSMSVGERVTLSCKASENVGTYVSWYQQKPKQSPK LLIYGTFNRYTGVPDRFTGSGSATDFTLTISSVQA EDLADYHCGQSYNYPFTFGSGTKLEIK VH QVQLQQSGAELARPGTSVKMSCKASGYTFTNYMMH 7 WIKQRPGQGLEWIGYINPSTGYTNYNQKFKDKATL TADKSSSTAYVQLNILTSEDSAVYYCATSTLITGD YWGQGTTLTVSSKGQDNSAG * The CDR sequences were marked in boldface, including three CDRs (i.e., CDR-L1, CDR-L2 anB · US 2023/0037864 A1 · ¶
A recombinant antibody comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein the VL domain comprises a first light chain complementarity determining region (CDR-L1), a second light chain CDR (CDR-L2) and a third light chain CDR (CDR-L3), and the VH domain comprises a first heavy chain CDR (CDR-H1), a second heavy chain CDR (CDR-H2) and a third heavy chain CDR (CDR-H3), wherein the CDR-L1, CDR-L2 and CDR-L3 respectively comprise the aminB · US 2023/0037864 A1 · claim 1
An empty cell means only that no passage was reproduced there.
Accordingly, there remains a need to develop a novel antibody that specifically binds to CD47 and blocks the signaling of CD47 and SIRPα.A · US 2022/0348652 A1 · ¶ 4
More particularly, the present disclosure relates to recombinant antibodies and uses thereof in the treatment of CD47-associated diseases, e.g., cancers.A · US 2022/0348652 A1 · ¶ 2
In view of the foregoing, there exists in the related art a need for a novel agent for treating PEDV infection so as to minimize the impact of PEDV on swine health and production.B · US 2023/0037864 A1 · ¶ 5
As embodied and broadly described herein, one aspect of the disclosure is directed to a recombinant antibody for the diagnosis and/or treatment of PEDV infection.B · US 2023/0037864 A1 · ¶ 7
patent.fyi, US 2026/0356926 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356926/, SHA-256 db43acf69ff770ab95b432ad44a0f6d7741997eabb79d2fcd549d1120eb2025f